Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12… (NCT05162443) | Clinical Trial Compass
APPROVED_FOR_MARKETINGNot Applicable
Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation
United States
Plain-language summary
The objective of this EAP is to provide expanded access of adagrasib (MRTX849) to patients with previously treated advanced solid tumors harboring a KRAS G12C mutation.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Histologically or cytologically confirmed diagnosis of an advanced/metastatic solid tumor
* Confirmed presence of a KRASG12C mutation
* Ineligible for an ongoing clinical trial of MRTX849
* No available or not eligible for standard of care treatment
* Adequate organ function
* CNS Metastases (within set parameters) are allowed
* ECOG performance status of ≤ 2
Exclusion Criteria:
* History of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions likely to alter absorption of MRTX849 treatment or result in inability to swallow
* Prior therapy targeting a KRAS G12C mutation
* Other active cancer